Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

Caspofungin and Pneumocystis Pneumonia: It Is Time To Go Ahead

Gilles Nevez, Solène Le Gal
Gilles Nevez
aGroupe d’Étude des Interactions Hôte-Pathogène (GEIHP)-EA 3142, Université de Brest, Brest, France
bLaboratoire de Mycologie et Parasitologie, CHRU de Brest, Brest, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Solène Le Gal
aGroupe d’Étude des Interactions Hôte-Pathogène (GEIHP)-EA 3142, Université de Brest, Brest, France
bLaboratoire de Mycologie et Parasitologie, CHRU de Brest, Brest, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01296-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

LETTER

We read with interest the article by Luraschi and colleagues on caspofungin and Pneumocystis jirovecii published in Antimicrobial Agents and Chemotherapy (1). Caspofungin is an echinocandin which is widely used as the first-line treatment of systemic candidiasis (2). This drug is a noncompetitive inhibitor of the subunit GSC1 of the enzymatic complex involved in 1,3-β-d-glucan synthesis, 1,3-β-glucan being a major cell wall component of most fungi. The main goal of the aforementioned study was to assess in vitro sensitivity of P. jirovecii, the human-specific Pneumocystis species, to caspofungin.

Nonsynonymous mutations that confer resistance to caspofungin have been identified on the gsc1 gene of the fungal pathogen C. albicans. The study performed by Luraschi and colleagues concerns site-directed mutagenesis based on mutations previously identified within the C. albicans gsc1 gene and the construction of Saccharomyces cerevisiae deletants for the gsc1 gene followed by their complementation with the gsc1 gene of wild or mutant P. jirovecii, Pneumocystis murina (the specific species in mice), and Pneumocystis carinii (the specific species in rats) organisms. The results showed that the drug was effective in vitro against P. jirovecii, P. murina, and P. carinii as well.

In vivo efficiency of caspofungin for treating Pneumocystis sp. infections has been established using rat and mouse models (3). Nonetheless, the drug essentially depletes Pneumocystis asci in the infected lungs, whereas it is less efficient against trophic forms (3). These results may be due to the absence or rarity of 1,3-β-d-glucan in trophic forms and the abundance of this component in ascus walls.

In this context, a potential synergistic combination based on low doses of caspofungin and co-trimoxazole and targeting asci and trophic forms has been evaluated using a mouse model. It was shown that P. murina could be eradicated within the lungs by this combined regimen (4). Similar combined regimens in patients with Pneumocystis pneumonia (PCP) have been reported (5–16) (Table 1).

View this table:
  • View inline
  • View popup
TABLE 1

Main reports on Pneumocystis pneumonia treatment using caspofungin

In a recent study, the gene expression profiles of P. murina were compared between infected untreated mice and those treated with an echinocandin; results suggested that ascus formation may be necessary for Pneumocystis proliferation (17). These findings may explain in part the efficiency of caspofungin monotherapy in patients developing P. jirovecii infections, as described in four case reports (eight patients) (18–21; Table 1). Conversely, three case reports described the apparent failure of caspofungin treatment in nine patients with PCP (21, 22, 23, Table 1). Thus, efficiency of echinocandins and specifically that of caspofungin to treat P. jirovecii infections in humans remains a subject of controversy.

Be that as it may, original results of Luraschi and colleagues that were obtained through a fundamental approach bring strong arguments for the use of caspofungin for PCP treatment in humans. These results render it necessary to implement clinical trials in order to revisit the approvals by the Food and Drugs Administration in the United States or the European Medicines Agency in Europe, which did not initially consider the use of caspofungin for PCP treatment.

FOOTNOTES

  • For the author reply, see https://doi.org/10.1128/AAC.01320-19.

  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Luraschi A,
    2. Richard S,
    3. Hauser PM
    . 2018. Site-directed mutagenesis of the 1,3-β-glucan synthase catalytic subunit of Pneumocystis jirovecii and susceptibility assays suggest its sensitivity to caspofungin. Antimicrob Agents Chemother 62:e01159-18. doi:10.1128/AAC.01159-18.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Pappas PG,
    2. Kauffman CA,
    3. Andes DR,
    4. Clancy CJ,
    5. Marr KA,
    6. Ostrosky-Zeichner L,
    7. Reboli AC,
    8. Schuster MG,
    9. Vazquez JA,
    10. Walsh TJ,
    11. Zaoutis TE,
    12. Sobel JD
    . 2016. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 15:e1–e50. doi:10.1093/cid/civ1194.
    OpenUrlCrossRef
  3. 3.↵
    1. Powles MA,
    2. Liberator P,
    3. Anderson J,
    4. Karkhanis Y,
    5. Dropinski JF,
    6. Bouffard FA,
    7. Balkovec JM,
    8. Fujioka H,
    9. Aikawa M,
    10. McFadden D,
    11. Schmatz D
    . 1998. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 42:1985–1989. doi:10.1128/AAC.42.8.1985.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Lobo ML,
    2. Esteves F,
    3. de Sousa B,
    4. Cardoso F,
    5. Cushion MT,
    6. Antunes F,
    7. Matos O
    . 2013. Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia: a pilot study in mice. PLoS One 8:e70619. doi:10.1371/journal.pone.0070619.
    OpenUrlCrossRef
  5. 5.↵
    1. Beltz K,
    2. Kramm CM,
    3. Laws HJ,
    4. Schroten H,
    5. Wessalowski R,
    6. Gobel U
    . 2006. Combined trimethoprim and caspofungin treatment for severe Pneumocystis jirovecii pneumonia in a five-year-old boy with acute lymphoblastic leukemia. Klin Padiatr 218:177–179. doi:10.1055/s-2006-933433.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Zhang JC,
    2. Dai JY,
    3. Fan J,
    4. Wu XP
    . 2006. The treatment of Pneumocystis carinii pneumonia with caspofungin in elderly patients: a case report and literature review. Zhonghua Jie He He Hu Xi Za Zhi 29:463–465.
    OpenUrlPubMed
  7. 7.↵
    1. Annaloro C,
    2. Volpe A,
    3. Usardi P,
    4. Lambertenghi Deliliers G
    . 2006. Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur J Clin Microbiol Infect Dis 25:52–54. doi:10.1007/s10096-005-0065-z.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Utili R,
    2. Durante-Mangoni E,
    3. Basilico C,
    4. Mattei A,
    5. Ragone E,
    6. Grossi P
    . 2007. Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe pneumocystis pneumonia in solid organ transplant recipients. Transplantation 84:685–688. doi:10.1097/01.tp.0000280546.91617.6c.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Mu XD,
    2. Que CL,
    3. He B,
    4. Wang GF,
    5. Li HC
    . 2009. Caspofungin in salvage treatment of severe Pneumocystis pneumonia: case report and literature review. Chin Med J 122:996–999.
    OpenUrl
  10. 10.↵
    1. Ceballos ME,
    2. Ortega M,
    3. Andresen M,
    4. Wozniak A,
    5. García P,
    6. Balcells ME
    . 2011. Successful treatment with echinocandin in an HIV-infected individual failing first-line therapy for Pneumocystis jirovecii pneumonia. AIDS 25:2192–2193. doi:10.1097/QAD.0b013e32834c4c3c.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Armstrong-James C,
    2. Stebbing J,
    3. John L,
    4. Murungi A,
    5. Bower M,
    6. Gazzard B,
    7. Nelson M
    . 2011. A trial of caspofungin salvage treatment in PCP pneumonia. Thorax 66:537–538. doi:10.1136/thx.2010.135350.
    OpenUrlFREE Full Text
  12. 12.↵
    1. Tu GW,
    2. Ju MJ,
    3. Xu M,
    4. Rong RM,
    5. He YZ,
    6. Xue ZG,
    7. Zhu TY,
    8. Luo Z
    . 2013. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients. Nephrology (Carlton) 18:736–742. doi:10.1111/nep.12133.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Lee WS,
    2. Hsueh PR,
    3. Hsieh TC,
    4. Chen FL,
    5. Ou TY,
    6. Jean SS
    . 2017. Caspofungin salvage therapy in Pneumocystis jirovecii pneumonia. J Microbiol Immunol Infect 50:547–548. doi:10.1016/j.jmii.2016.03.008.
    OpenUrlCrossRef
  14. 14.↵
    1. Lu YM,
    2. Lee YT,
    3. Chang HC,
    4. Yang HS,
    5. Chang CY,
    6. Huang CM,
    7. Wei J
    . 2017. Combination of echinocandins and trimethoprim/sulfamethoxazole for the treatment of Pneumocystis jiroveci pneumonia after heart transplantation. Transplant Proc 49:1893–1898. doi:10.1016/j.transproceed.2017.04.020.
    OpenUrlCrossRef
  15. 15.↵
    1. Zhang G,
    2. Chen M,
    3. Zhang S,
    4. Zhou H,
    5. Ji X,
    6. Cai J,
    7. Lou T,
    8. Cui W,
    9. Zhang N
    . 2018. Efficacy of caspofungin combined with trimethoprim/sulfamethoxazole as first-line therapy to treat non-HIV patients with severe pneumocystis pneumonia. Exp Ther Med 15:1594–1601. doi:10.3892/etm.2017.5516.
    OpenUrlCrossRef
  16. 16.↵
    1. Koshy R,
    2. Chen T
    . 2019. Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe Pneumocystis pneumonia. ID Cases 15:e00496. doi:10.1016/j.idcr.2019.e00496.
    OpenUrlCrossRef
  17. 17.↵
    1. Cushion MT,
    2. Ashbaugh A,
    3. Hendrix K,
    4. Linke MJ,
    5. Tisdale N,
    6. Sayson SG,
    7. Porollo A
    . 2018. Gene expression of Pneumocystis murina after treatment with anidulafungin results in strong signals for sexual reproduction, cell wall integrity, and cell cycle arrest, indicating a requirement for ascus formation for proliferation. Antimicrob Agents Chemother 62:e02513-17. doi:10.1128/AAC.02513-17.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Hof H,
    2. Schnülle P
    . 2008. Pneumocystis jiroveci pneumonia in a patient with Wegener's granulomatosis treated efficiently with caspofungin. Mycoses 51:65–67. doi:10.1111/j.1439-0507.2008.01530.x.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Lee N,
    2. Lawrence D,
    3. Patel B,
    4. Ledot S
    . 2017. HIV-related Pneumocystis jirovecii pneumonia managed with caspofungin and veno-venous extracorporeal membrane oxygenation rescue therapy. BMJ Case Rep doi:10.1136/bcr-2017-221214.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Huang HB,
    2. Peng JM,
    3. Du B
    . 2018. Echinocandins for Pneumocystis jirovecii pneumonia in non-HIV patients: A case report. Exp Ther Med 16:3227–3232. doi:10.3892/etm.2018.6587.
    OpenUrlCrossRef
  21. 21.↵
    1. Huang YS,
    2. Liu CE,
    3. Lin SP,
    4. Lee CH,
    5. Yang CJ,
    6. Lin CY,
    7. Tang HJ,
    8. Lee YC,
    9. Lin YC,
    10. Lee YT,
    11. Sun HY,
    12. Hung CC
    , Taiwan HIV Study Group. 2019. Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia. AIDS 33:1345–1351. doi:10.1097/QAD.0000000000002207.
    OpenUrlCrossRef
  22. 22.↵
    1. Kamboj M,
    2. Weinstock D,
    3. Sepkowitz KA
    . 2006. Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin Infect Dis 43:e92–e94. doi:10.1086/508282.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Kim T,
    2. Hong HL,
    3. Lee YM,
    4. Sung H,
    5. Kim SH,
    6. Choi SH,
    7. Kim YS,
    8. Woo JH,
    9. Lee SO
    . 2013. Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review. Scand J Infect Dis 45:484–488. doi:10.3109/00365548.2012.760842.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
Caspofungin and Pneumocystis Pneumonia: It Is Time To Go Ahead
Gilles Nevez, Solène Le Gal
Antimicrobial Agents and Chemotherapy Sep 2019, 63 (10) e01296-19; DOI: 10.1128/AAC.01296-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Caspofungin and Pneumocystis Pneumonia: It Is Time To Go Ahead
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Caspofungin and Pneumocystis Pneumonia: It Is Time To Go Ahead
Gilles Nevez, Solène Le Gal
Antimicrobial Agents and Chemotherapy Sep 2019, 63 (10) e01296-19; DOI: 10.1128/AAC.01296-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

caspofungin
echinocandin
Pneumocystis jirovecii

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596